ASND stock news
This page provides real-time market news, earnings updates, and company announcements related to Ascendis Pharma A/S (ASND).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-07-16 06:10 EST
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026
Finviz2026-02-12 17:48:41
Ascendis Pharma (ASND) Revenue Nearly Doubles to 720M in 2025 Fueled by Core Product Growth
Finviz2026-02-20 09:12:44
FDA Approves Once-Weekly YUVIWEL (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
Finviz2026-02-27 23:00:45
Ascendis Wins FDA Approval For Rare Disease Therapy
Finviz2026-03-02 13:03:56
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
Finviz2026-03-19 12:04:20
Rani Therapeutics Appoints Jesper Hoiland as Head of Strategy to Advance Corporate and Pipeline Prioritization
Finviz2026-03-25 20:57:45
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
Finviz2026-03-31 12:03:48
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
Finviz2026-03-19 12:04:20
Rani Therapeutics Appoints Jesper Hoiland as Head of Strategy to Advance Corporate and Pipeline Prioritization
Finviz2026-03-25 20:57:45
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
Finviz2026-03-31 12:03:48
ASND stock chart
ASND stock detailsASND stock price change
On the last trading day, ASND stock closed at 267.84 USD, with a price change of 0.85% for the day.
Trade spot stocks (24/7)Trade stock perps (up to 100x leverage)About Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
To provide deeper liquidity, a more transparent trading experience, and greater capital efficiency, Bitget officially launched its all-new spot stock product, Bitget Stocks 2.0, on June 2, 2026.
The new product is independently issued by licensed RWA protocol Reality, with Bitget providing strategic support and asset security safeguards. This marks a major upgrade to the stock trading experience.
Bitget is moving stock trading beyond the limits of traditional trading models by fully integrating stock assets into its margin and yield ecosystem.
Learn more